A closely watched therapy developed by Johnson & Johnson failed to show a statistically meaningful improvement for IBD patients.
Jeff Schear/Getty Images for Johnson & Johnson
By Allison DeAngelis
May 5, 2026
Biotech Startups and Venture Capital Reporter
Allison DeAngelis
Cytokinetics' Myqorzo's trial results, Johnson & Johnson's IBD therapy, and more biotech news from The Readout
Johnson & Johnson said it discontinued a mid-stage study of its experimental drug to treat atopic dermatitis, after it…
Last year, Johnson & Johnson arrived late to the party with Imaavy as the third FcRn blocker
J&J’s shares ticked down as oncology sales missed expectations. Elsewhere, AstraZeneca bet $600 million on a lung cancer drug and…
New data suggest Imaavy could be an effective treatment for autoimmune anemia. Elsewhere, Enliven detailed data for a Merck…
Johnson & Johnson expands its biotech pipeline with Firefly Bio acquisition and a strategic partnership with Sail Biomedicines.
